With the expiration of the 2020-2024 UNL-NFU-UKB-NWO-Elsevier agreement, also the Open Science pilot program will end. 

We thank all the participating institutions, the members of the steering group and executive board, and the pilot participants for their ongoing commitment that made this unique collaboration a success. In total 8 pilots ran with nearly 60 participating institutions. For an evaluation of the pilots please see: here

Please be advised that the pilots will be discontinued by end of December 2024 unless otherwise communicated with the participating institutions

If you would like to discuss the continuation of EquipmentMonitor, Author Disambiguation Service, and/or the (successor of) DataMonitor, please contact: Dino Venturino at d.venturino@elsevier.com.  

Discussions about the continuation of RareDiseaseMonitor (for the NFU members) are ongoing.   

More information about the new 2025-2027 Agreement will be added to the Elsevier  Open Access agreements page in due course.  

The epdos.nl website will continue to be accessible through the first half of 2025.

PILOT

Rare Diseases Monitor

Status: Pilot completed, Running as a service

Link to live dashboard

 

Participating Institutions

Erasmus MC, Amsterdam MC and UMC Groningen on behalf of the NFU

The aim of this pilot is to provide public access to insights (articles, metadata, other information) about rare (or orphan) disease research activities in the Netherlands to researchers, institutions, patient organisations and, Research funders and other stakeholders in health care.

 

How the pilot works

The pilot will use the so-called Orpha.net taxonomy (publicly available CC-BY 4.0) that describes almost all known rare diseases. The pilot will apply that taxonomy to the corpus of academic literature to create fields that can be searched, described and also quantified, by using a vocabulary created by SciBite (part of Elsevier) that allows for precision search and a high level of accuracy, finding articles that match the Orpha codes. This will enable the partners to answer questions, such as:

  • Patient: ‘Where is the nearest hotspot of academic research in my disease?’
  • PI/researchers: ‘Who would be the best collaborator on this European grant proposal?’
  • GP: ‘Whom should I refer this patient to?’
  • Research funder: ‘How much work is being done in this disease that is currently without a cure?

 

Support of open science and benefits to researchers and institutions

An open system/tool that provides insights in Rare Disease research (creating visibility of outputs and outcomes per disease or disease cluster) is beneficial for:

  • research groups and institutions (showcase expertise to the public, and stimulate collaborations)
  • patient groups (finding experts and expert centres of specific rare diseases)
  • Research Funders, such as ZonMW
  • the pharmaceutical industry and health insurers (research developments and trends).

It helps to make the existing evaluation processes more efficient and supports Evidence Based Medicine (the medical practice or care that emphasizes the practical application of the findings of the best available current research)

 

Relevant links

 

For more information on how to participate in this pilot, please reach out to Guillaume Warnan, or contact us.

Copyright © The Partners 2022, under a creative commons license

en_USEnglish